A supplement to Clinical Psychiatry News supported by an unrestricted educational grant from Pfizer.
This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education/Excerpta Medica, Inc., an ACCME accredited provider, and Clinical Psychiatry News.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 15.
Faculty
A. Eden Evins, MD
Assistant Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston Grant/Research Support: Pfizer, Inc.; Consultant: Janssen Pharmaceutica Products, L.P.; Speaker's Bureau: AstraZeneca and Janssen. She discusses the off-label uses of antipsychotic drugs.
Jeffrey A. Lieberman, MD
Thad and Alice Eure Distinguished Professor of Psychiatry
Vice Chairman, Department of Psychiatry
University of North Carolina School of Medicine
Chapel Hill Grant/Research Support: AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Janssen, Novartis AG, Organon USA, Pfizer and Sanofi-Synthelabo; Consultant: AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer and Solvay S.A.; Advisory Board: AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Organon, Pfizer and Solvay; Speaker's Bureau: Lilly.
Herbert Y. Meltzer, MD
Bixler Professor of Psychiatry and Pharmacology
Director, Division of Psychopharmacology
Department of Psychiatry
Vanderbilt University Medical Center
Nashville, Tenn Grant/Research Support/Consultant: AstraZeneca, Bristol-Myers Squibb, Lilly, Janssen, Solvay, and Pfizer; Consultant: Ovation Pharma.
Topics
Introduction
Comorbid Anxiety Disorders
Agitation and Aggression: New Treatment Options
Depression and Suicidality in Schizophrenia
Cognitive Dysfunction and Clinical Outcome
Target Audience
This activity has been developed for psychiatrists and other health care professionals who treat patients diagnosed with schizophrenia or schizoaffective disorder.
Educational Needs
To optimize clinical and functional status of individuals diagnosed with schizophrenia, identification and treatment of more than the classical positive and negative symptoms are recommended. Symptom domains reflecting comorbid anxiety, agitation, aggression, violence, depression, hopelessness, suicidality, or cognitive dysfunction represent compelling targets for focused intervention. Consequentially, opportunities to improve daily quality of life, therapeutic alliance, medication adherence, long-term stability, social interaction, and functional outcome are afforded well-informed clinicians. Toward this end, prevalence, consequences, and treatment options for these common comorbidities of schizophrenia are discussed.
Learning Objectives
By reading and studying this supplement, participants should be able to:
• Identify symptom domains that may complicate the treatment of schizophrenia.
• Discuss the prevalence of comorbid anxiety, depression, and cognitive dysfunction.
• Recognize acute agitation, its significance and treatment options.
• Specify risk factors for suicide among patients with schizophrenia.
• Appreciate the far-reaching consequences of these comorbidities among patients with schizophrenia.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (OCME)/Excerpta Medica, Inc., and Clinical Psychiatry News. The Elsevier OCME/Excerpta Medica is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier OCME/Excerpta Medica designates this educational activity for a maximum of 1.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.
The American Medical Association has determined that non-US licensed physicians who participate in this activity are eligible for AMA/Physician's Recognition Award category 1 credit.
